Abiopharma

🔍 Kapani Mayur (Executive)

Company: Intercontinental Exchange, Inc. (ICE)

Report Date: 2026-08-12

Detailed Transactions and Holdings:

• Acquired 4,271 shares of Common Stock at $67.0 per share (Direct)
  Date: 2026-08-12 | Code: M | equity_swap_involved: false | shares_owned_after: 69,231.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 3,028 shares of Common Stock at $57.31 per share (Direct)
  Date: 2026-08-12 | Code: M | equity_swap_involved: false | shares_owned_after: 72,259.00 | transaction_form_type: 4
• Sold 400 shares of Common Stock at $149.8286 per share (Direct)
  Date: 2026-08-12 | Code: S | equity_swap_involved: false | shares_owned_after: 71,859.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Sold 3,771 shares of Common Stock at $151.3268 per share (Direct)
  Date: 2026-08-12 | Code: S | equity_swap_involved: false | shares_owned_after: 68,088.00 | transaction_form_type: 4 | Footnotes: F1, F4
• Sold 100 shares of Common Stock at $151.78 per share (Direct)
  Date: 2026-08-12 | Code: S | equity_swap_involved: false | shares_owned_after: 67,988.00 | transaction_form_type: 4 | Footnotes: F1, F5
• Sold 3,028 shares of Employee Stock Option (right to buy) Holding at $57.31 per share (Derivative)
  Date: 2026-08-12 | Code: M | Expires: 2027-01-18 | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F8
• Sold 4,271 shares of Employee Stock Option (right to buy) Holding at $67.0 per share (Derivative)
  Date: 2026-08-12 | Code: M | Expires: 2028-02-08 | equity_swap_involved: false | shares_owned_after: 5,764.00 | transaction_form_type: 4 | Footnotes: F8

Footnotes:

• F1: This transaction was effected pursuant to a Rule 10b5-l trading plan which was approved and became effective as of February 12, 2026.
• F2: Amount of securities beneficially owned includes 91 shares acquired under Intercontinental Exchange, Inc. Employee Stock Purchase Plan on June 30, 2026.
• F3: The price range for the aggregate amount sold by the direct holder is $149.55 - $150.25. The Issuer will upon request by the Staff of the U.S. Securities and Exchange Commission or a security holder of the Issuer provide the full information regarding the number of shares sold at each separate price.
• F4: The price range for the aggregate amount sold by the direct holder is $150.76 - $151.71. The Issuer will upon request by the Staff of the U.S. Securities and Exchange Commission or a security holder of the Issuer provide the full information regarding the number of shares sold at each separate price.
• F5: The common stock number referred in Table I is an aggregate number and represents 56,779 shares of common stock, 8,907 unvested restricted stock units ("RSUs"), and 2,302 performance based restricted stock units ("PSUs"), for which the performance period has been satisfied. The RSUs and PSUs vest over a three-year period, in which 33.33% of the units vest each year.
• F6: The satisfaction of the 2024, 2025 and 2026 three-year total shareholder return ("TSR") PSUs and the corresponding number of shares to be issued pursuant to these awards, will not be determined until February 2027, February 2028 and February 2029, respectively, and will be reported at the time of vesting. The satisfaction of the 2024, 2025 and 2026 three-year earnings before interest, taxes, depreciation, and amortization ("EBITDA") PSUs and the corresponding number of shares to be issued pursuant to these awards, will not be determined until February 2027, February 2028 and February 2029, respectively, and will be reported at the time of vesting.
• F7: The satisfaction of the performance based restricted stock units granted as Deal Incentive Awards and the corresponding number of shares to be issued pursuant to these awards, will not be determined until December 2026, December 2027 and December 2028 and will be subject to additional time-based vesting conditions and, if applicable, a subsequent one-year holding period.
• F8: These options are fully vested.